Zynerba plummets 51% after its CBD gel fails trial for rare disease (ZYNE) – Business Insider
Zynerba, a small biotechnology company, plummeted 51% on Tuesday after its CBD gel failed a pivotal trial for a rare disorder called Fragile X syndrome. The company said its experimental…
Share